May 2005
Worldwide Biotech;May2005, Vol. 17 Issue 5, p1
Trade Publication
Reports on a joint drug discovery program being pursued by the Global Alliance for TB Drug Development and GlaxoSmithKline to improve the treatment of tuberculosis (TB). Advantage of the program; Number of projects included in the joint research program; Goal of the TB Alliance.


Related Articles

  • GSK'S Centres of Excellence for External Drug Discovery.  // Bio Outsourcing Asia;Mar2011, Vol. 3 Issue 4, p11 

    The article describes GlaxoSmithKline's (GSK) Centres of Excellence for External Drug Discovery (CEEDD). GSK's CEEDD is a pioneering team of about 25 people in GSK research and development tasked with forming multi-program, risk reward sharing alliances across all therapy areas. A CEEDD alliance...

  • GSK's Academic Competition Aims to Accelerate Innovation. Moran, Nuala // BioWorld Today;5/22/2013, Vol. 24 Issue 98, p1 

    The article features the Discovery Fast Track, a competition on drug development concept sponsored by GlaxoSmithKline (GSK) plc for academics in North America. The entry should be a one-page proposal on any therapeutic field to be submitted before July 19, 2013, wherein the 10 winner will be...

  • Amicus Lands $230M Deal for Fabry Chaperone Amigal. Boggs, Jennifer // BioWorld Today;11/1/2010, Vol. 21 Issue 211, p1 

    The article reports on the partnership deal worth 230 million dollars of Amicus Therapeutics Inc. and GlaxoSmithKline (GSK) plc for Fabry disease drug Amigal. GSK agreed to pay Amicus 30 million dollars in cash up front and take a 19.9% equity stake. Aside from the up-front money, Amicus is...

  • GSK Announces Singapore Collaborations…. PROFFITT, ALLISON // Bio-IT World;Nov/Dec2010, Vol. 9 Issue 6, p10 

    The article reports on the academic partnerships of GlaxoSmith Kline with four academic groups in Singapore regarding drug discovery. The article mentions that the partnership awards went to Duke-NUS Graduate Medical School, Singapore Eye Research Institute, A*STAR-Singapore Institute for...

  • Oxford BioTherapeutics, GSK in $370M Cancer Drug Deal. Young, Donna // BioWorld Today;5/19/2009, Vol. 20 Issue 95, p1 

    The article reports on the partnership of British biotechnology company Oxford BioTherapeutics Ltd. with pharmaceutical firm GlaxoSmithKline plc (GSK) to discover, develop and commercialize therapeutic antibodies aimed at treating primary, metastatic and recurring forms of cancer. Chief...

  • GSK Deal Adds to Five Prime's List of Big Pharma Conquests. Serebrov, Mari // BioWorld Today;4/18/2012, Vol. 23 Issue 75, p1 

    The article reports on the second partnership forged by Five Prime Therapeutics with GlaxoSmithKline plc (GSK) under which GSK will be given access to the drug discovery platforms of the biotechnology firm. Aside from the drug discovery platforms, GSK will also have access to Five Prime's...

  • GSK Takes on 3 More Prosensa Exon-Skipping DMD Drugs. Sheridan, Cormac // BioWorld Today;9/14/2011, Vol. 22 Issue 178, p2 

    This article explains that Prosensa Therapeutics BV and GlaxoSmithKline PLC are pursuing with three additional exon-skipping antisense oligonucleotides as part of their joint efforts in Duchenne's muscular dystrophy (DMD) research. It explains that GlaxoSmithKline has acquired options of three...

  • GlaxoSmithKline Shortens R&D Cycle with JMP's Design of Experiments. Smith, Amy // Scientific Computing & Instrumentation;Oct2002, Vol. 19 Issue 11, p20 

    Explores the impact of statistical investigation of collected data on the drug development stage with reference to the experience of GlaxoSmithKline (GSK). Stages of drug development; Aim of GSK for shortened research and development cycle; Benefits of statistical investigation in drug development.

  • Pending Merger, Archemix Inks Potential $1.4B Deal with GSK. Hollingsworth, Catherine // BioWorld Today;12/24/2008, Vol. 19 Issue 249, p1 

    The article reports on a deal forged between Archemix Corp. and GlaxoSmithKline (GSK) plc to discover, develop and commercialize aptamer therapeutics for inflammatory diseases. The deal increased Archemix's finances with $27.5 million. Under the deal, Alchemix will receive an initial payment of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics